Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (91-100 of 274) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Clinical Lung Cancer|January 15, 2004
Antisense oligonucleotides in the treatment of non-small-cell lung cancerAngela M Davies, David R Gandara, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancerDavid R Gandara, Peter Grimminger, Philip C Mack, et al.
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Chemical Research in Toxicology|October 30, 2010
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsSisi Wang, Hongyong Zhang, Michael Malfatti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Predictive molecular markers: has the time come for routine use in lung cancer?Angela M Davies, Philip C Mack, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
JCO Oncology Practice|November 18, 2025
Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World DataSarmad Sadeghi, Primo N Lara, Andrea Necchi, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
Clinical Lung Cancer|October 10, 2006
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)David R Gandara, Kari Chansky, Kathy S Albain, et al.
Pageof 28

Showing results (91-100 of 274) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|November 2, 2013
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsDavid R Gandara, Tianhong Li, Primo N Lara, et al.
Clinical Lung Cancer|January 15, 2004
Antisense oligonucleotides in the treatment of non-small-cell lung cancerAngela M Davies, David R Gandara, Primo N Lara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancerDavid R Gandara, Peter Grimminger, Philip C Mack, et al.
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Chemical Research in Toxicology|October 30, 2010
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsSisi Wang, Hongyong Zhang, Michael Malfatti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 26, 2009
Predictive molecular markers: has the time come for routine use in lung cancer?Angela M Davies, Philip C Mack, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
JCO Oncology Practice|November 18, 2025
Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World DataSarmad Sadeghi, Primo N Lara, Andrea Necchi, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
Clinical Lung Cancer|October 10, 2006
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)David R Gandara, Kari Chansky, Kathy S Albain, et al.
Pageof 28